Earlier this week we announced that the National Institutes of Health granted $23 million to the Phase III study of isradipine to slow the progression of Parkinson's disease. This drug is currently approved to treat high blood pressure.

The ABC news station in Rochester, New York ran a segment on the study on April 2. Kevin Biglan, MD, MPH, is associate chair for clinical research in the Department of Neurology at the University of Rochester and co-principal investigator of the isradipine study.

Listen to a podcast with Tanya Simuni, MD, director of the Parkinson’s Disease and Movement Disorders Program at Northwestern University and principal investigator of the trial.